Septic Shock & Cancer
Proposed Patient Trial
Survive Cancer is hoping to run a patient trial to test very high doses of vitamin B12 in the treatment of septic shock.
What is Septic Shock?
Septic shock kills at least 50% of its victims. It happens when the body is overtaken by infection. The circulation fails, the organs collapse and the person can die.
Who gets it?
Examples include children with meningitis, old people with pneumonia, 67% of cancer patients, AIDS patients, transplant patients, accident victims and patients contracting the hospital super-bug MRSA. Avian flu can also result in septic shock.
Why should we do this trial?
Animal trials going back half a century testing B12 in the treatment of septic shock have shown that it works. • Vitamin B12 has a supremely good safety record – in France they use mega doses to treat cyanide poisoning. • Despite the use of antibiotics, there is currently no successful treatment for septic shock. • Drug companies will never fund this trial – there is no commercial value to them, as vitamins are not patentable. • If successful, we would have a cheap treatment which will have worldwide implications for healthcare costs and, quite simply, human life.
The history of the project
Dr Carmen Wheatley set up Survive Cancer in 1999 to promote an integrated approach to cancer treatment. We believe that it is basic commonsense to boost the overall health of your body’s immune system when you are ill, using vitamins, minerals, herbs and other natural therapies – known as orthomolecular medicine – especially when you are undergoing chemo and radio-therapy. (It is estimated that 67% of cancer patients die from infections brought on by a weakened immune system.) During her research into orthomolecular solutions to disease, Carmen found successful animal studies testing vitamin B12 in the treatment of septic and traumatic shock.
Dr Wheatley has published three hypotheses on B12 for septic shock, in respected medical journals. Her work has attracted international interest from scientists in the field of inflammation. Professors from Harvard, London and Milan have offered to collaborate. We have just completed a number of very successful preliminary lab studies at the William Harvey Institute, London, conducted by Professor Mauro Perretti and his colleagues Professor Fulvio D`Acquisto and Dr Andre Sampaio.
Why this is exciting
Rigorous patient trials are essential if we are to test new approaches to disease. Now we have a chance to do just this, with a vitamin that has been proved to have an excellent safety record in high doses, to treat a life-threatening condition which conventional medicine has so far failed to cure. We have the attention of serious, internationally renowned scientists and doctors, eager to test, yes, a vitamin! If it works, it will be a life-saver for millions.